TY - JOUR
T1 - Myriad functions of stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF)
AU - Ohkouchi, Shinya
AU - Ono, Manabu
AU - Kobayashi, Makoto
AU - Hirano, Taizou
AU - Tojo, Yutaka
AU - Hisata, Shu
AU - Ichinose, Masakazu
AU - Irokawa, Toshiya
AU - Ogawa, Hiromasa
AU - Kurosawa, Hajime
PY - 2015/12/29
Y1 - 2015/12/29
N2 - Idiopathic pulmonary fibrosis (IPF) is an intractable disease for which the pathological findings are characterized by temporal and spatial heterogeneity. The pathogenesis is composed of myriad factors, including repetitive injuries to epithelial cells, alterations in immunity, the formation of vascular leakage and coagulation, abnormal wound healing, fibrogenesis, and collagen accumulation. Therefore, the molecular target drugs that are used or attempted for treatment or clinical trials may not cover the myriad therapeutic targets of IPF. In addition, the complicated pathogenesis results in a lack of informative biomarkers to diagnose accurately the status of IPF. These facts point out the necessity of using a combination of drugs, that is, each single drug with molecular targets or a single drug with multiple therapeutic targets. In this review, we introduce a humoral factor, stanniocalcin-1 (STC1), which has myriad functions, including the maintenance of calcium homeostasis, the promotion of early wound healing, uncoupling respiration (aerobic glycolysis), reepithelialization in damaged tissues, the inhibition of vascular leakage, and the regulation of macrophage functions to keep epithelial and endothelial homeostasis, which may adequately cover the myriad therapeutic targets of IPF.
AB - Idiopathic pulmonary fibrosis (IPF) is an intractable disease for which the pathological findings are characterized by temporal and spatial heterogeneity. The pathogenesis is composed of myriad factors, including repetitive injuries to epithelial cells, alterations in immunity, the formation of vascular leakage and coagulation, abnormal wound healing, fibrogenesis, and collagen accumulation. Therefore, the molecular target drugs that are used or attempted for treatment or clinical trials may not cover the myriad therapeutic targets of IPF. In addition, the complicated pathogenesis results in a lack of informative biomarkers to diagnose accurately the status of IPF. These facts point out the necessity of using a combination of drugs, that is, each single drug with molecular targets or a single drug with multiple therapeutic targets. In this review, we introduce a humoral factor, stanniocalcin-1 (STC1), which has myriad functions, including the maintenance of calcium homeostasis, the promotion of early wound healing, uncoupling respiration (aerobic glycolysis), reepithelialization in damaged tissues, the inhibition of vascular leakage, and the regulation of macrophage functions to keep epithelial and endothelial homeostasis, which may adequately cover the myriad therapeutic targets of IPF.
KW - Biomarker
KW - Idiopathic pulmonary fibrosis (IPF)
KW - Macrophage
KW - Stanniocalcin-1 (STC1)
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=84960420135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960420135&partnerID=8YFLogxK
U2 - 10.4137/CCRPRPM.S23285
DO - 10.4137/CCRPRPM.S23285
M3 - Article
AN - SCOPUS:84960420135
VL - 9
SP - 91
EP - 96
JO - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
JF - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
SN - 1179-5484
ER -